Lytix Biopharma ASA

kr 7.90As of Sun 8 Nov 2026, 12:00 UTC
OSL:LYTIXHealthcare
Country Norway
PE (Fwd) •••
TSR 5Y CAGR (9.93%)
Div yield —
ROE (107.13%)
Biotechnology
Beta (5Y) (0.51)
PE TTM —
TSR TTM 3.08%
Mkt cap kr 607.5M
ROIC (68.38%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
kr 9.50
20.20%
(84.60%)
Hold 2|9|4|7|10
4Q25
1Q26
2Q26
3Q26
Earnings per sharekr
0.13
0.15
0.14
0.15
38.76%
38.01%
18.37%
17.46%
Revenuekr M
29.75
31.08
31.20
31.20
3.05%
8.18%
4.34%
5.58%
Peers (US$64.26M)
Cap (US$)
PE
52.12M
—
40.58M
—
64.32M
—
Capital
TTM
5Y
10Y
Leveragex
1.302
(0.098)
(0.095)
EBIT/Intx
2.261
0.042
0.042
Own earn%
(25.41)
(46.87)
11.09
Sh yield%
21.25
39.34
35.41
Owners
Insiders/Inst%
3.66
56.36
Short interest%
1.86
SBC / revenue%
4.22
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
22
Op margin range%
12–15
$1 testx
—
Incr. ROIC%
5